Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is GBX 1,939.17 ($24.27).
Several research firms have issued reports on HIK. Barclays boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 ($21.27) to GBX 1,800 ($22.53) and gave the stock an “equal weight” rating in a research note on Wednesday, July 12th. Jefferies Financial Group boosted their price objective on shares of Hikma Pharmaceuticals from GBX 2,080 ($26.03) to GBX 2,125 ($26.59) and gave the stock a “buy” rating in a research note on Monday, May 22nd.
Hikma Pharmaceuticals Price Performance
Hikma Pharmaceuticals Cuts Dividend
The company also recently announced a dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 10th were paid a $0.25 dividend. The ex-dividend date was Thursday, August 10th. This represents a dividend yield of 0.95%. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is presently 9,245.28%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded.
- Five stocks we like better than Hikma Pharmaceuticals
- What Are MATANA Stocks?
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Consumer Staples Stocks, Explained
- MarketBeat Week in Review – 9/11 – 9/15
- Why Invest in 5G? How to Invest in 5G Stocks
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.